US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Prostatype Genomics announces outcome of exercise of warrants of series 3 (TO3)

Prostatype Genomics AB ("Prostatype Genomics" or the "Company") today announces the outcome of the exercise period for warrants of series 3 (the "Warrants" or “TO3”) issued in connection with Prostatype Genomics rights issue of units announced on 7 November 2023 (the “Rights Issue”). A total of 202,524,736 Warrants were exercised, of which 20,000,000 by offsetting claims, corresponding to a subscription rate of approximately 81.0 percent. Prostatype Genomics receives proceeds of approximately SEK 7.3 million before issuing costs.“We have recently announced several important advances for the

Prostatype Genomics announces very strong interim results from long-term follow-up study with Prostatype® in Uppsala

Prostatype Genomics AB ("Prostatype Genomics" or the "Company") announces that interim results from 180 of a total of approximately 500 patients in the ongoing long-term follow-up study at Akademiska University Hospital in Uppsala, Sweden, with the Company's genetic test Prostatype® show excellent accuracy for Prostatype® even after 20 years of follow-up time after diagnosis. None of the analysed patients classified as low risk by Prostatype® died from their prostate cancer during 20 years of follow-up time. The interim results from the Uppsala study, together with data from the ongoing US

Prostatype Genomics updates on significant progress in the US study with Prostatype®

Prostatype Genomics AB (”Prostatype Genomics” or ”the Company”) announces that the US study with Prostatype®, which includes approximately 1,200 patients with prostate cancer with a broad ethnicity coverage, is progressing significantly faster than expected. Approximately 40% of the entire study has already been completed. The Company will compile interim data from the study and apply to get Prostatype® approved for reimbursement in the United States by Medicare when approximately 150 African American patients have been analysed. The Company expects to submit the Medicare application in Q2-Q3

Prostatype Genomics announces strong positive final results from multicentre study with Prostatype® in Spain

Prostatype Genomics (”Prostatype Genomics” or ”the Company”) announces that the retrospective multicentre study in Spain with the Company’s gene test Prostatype®, which includes 126 patients with prostate cancer at seven hospitals and is coordinated by the Spanish National Urology Association, has now been completed with strong positive results. The final results show that the treatment plan could have been modified for 39% of the patients if Prostatype® had been used as a decision basis at the time of diagnosis. Prostatype® was launched in Spain in 2023, and Prostatype Genomics now see good

The exercise period for Prostatype Genomic’s warrants of series 3 begins today

The exercise period for the warrants of series 3 (the "Warrants" or “TO3”) issued in connection with Prostatype Genomic AB ("Prostatype Genomics" or the "Company") rights issue of units announced on November 7, 2023 (the "Rights Issue") begins today and runs up to, and including, April 19, 2024. The exercise price is set at SEK 0.04 per share. Each Warrant entitles the holder to subscribe for one new share in Prostatype Genomics, and upon full exercise of the Warrants, the Company will receive approximately SEK 10.0 million before deductions for issuing costs.“From today you can exercise

Prostatype Genomics enters into collaboration with Professor E. David Crawford, MD, University of California San Diego, in preparation for the commercial launch of Prostatype® in the United States

Prostatype Genomics announces that the company and Professor E. David Crawford, MD, an internationally recognized expert in prostate cancer, will be the first US urologist with access to the Prostatype® testing service for clinical use. Providing early access and partnering with Professor Crawford in preparation for release nationwide will help ensure that urologist’s expectations are met when launching this next generation of prognostic testing to benefit patients battling prostate cancer.Prostatype Genomics has recently communicated the fulfillment of several key regulatory milestones

Prostatype Genomics publishes newsletter on US progress and the long-term follow-up study in Uppsala

Prostatype Genomics today publishes a newsletter for January–February 2024 with a CEO interview on what the three recently published advances in the United States mean for the company from an investor perspective, as well as an in-depth interview about the ongoing long-term follow-up study with Prostatype®, the company's gene test for prostate cancer patients, at Uppsala University Hospital.CEO Fredrik Persson explains the significance of the recently achieved milestones on the way to the US marketFredrik explains the significance of the three milestones achieved in the United States in

Prostatype Genomics’ long-term study with Uppsala University Hospital will be presented at the AUA conference in the US in May 2024

Prostatype Genomics announces that the interim results from the long-term follow-up study with the genetic test Prostatype®, which is conducted by and in collaboration with Uppsala University Hospital, has been accepted for presentation at the annual AUA (American Urological Association) conference in the United States in May 2024. To be accepted for presentation at this leading urology conference in the world’s largest market for prostate cancer diagnostics and prediction shows that there is a substantial interest for the study and the clinical potential of Prostatype® among American

Prostatype Genomics publishes year-end report for 2023 - supplement

The supplement relates to the year-end report attachment, which was not attached to the previous press release.  Prostatype Genomics AB today publishes its year-end report for the full year 2023, including the interim report for the second half of 2023. The full year-end report is attached and can also be downloaded from the company’s website, www.prostatypegenomics.com.Summary of the second half of the year and the full year 2023 Second half of 2023, 1 July 2023 – 31 December 2023• Net sales amounted to 908 TSEK (414)• EBITDA (earnings before interest, taxes, depreciation, and

Prostatype Genomics publishes year-end report for 2023

Prostatype Genomics AB today publishes its year-end report for the full year 2023, including the interim report for the second half of 2023. The full year-end report is attached and can also be downloaded from the company’s website, www.prostatypegenomics.com.Summary of the second half of the year and the full year 2023 Second half of 2023, 1 July 2023 – 31 December 2023• Net sales amounted to 908 TSEK (414)• EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -17,797 TSEK (-14,849)• Cash flow from current operations amounted to -9,938 TSEK (-16,386)

Prostatype Genomics receives CAP laboratory accreditation, achieves another milestone towards entering the US market

Prostatype Genomics AB ("Prostatype Genomics" or "the Company") announces that its wholly-owned US subsidiary Prostatype Genomics, Inc. has been accredited by the CAP (College of American Pathologists) Laboratory Accreditation Program. The Company has thus achieved three major regulatory milestones in February 2024 towards entering the US market: a signed CLIA laboratory agreement with its lab partner ResearchDx, acquisition of a CLIA Certificate, and now CAP laboratory accreditation. The final regulatory step needed before being able to enter the US prostate cancer market is a formal

Prostatype Genomics acquires CLIA Certificate to facilitate rapid US market launch with a significantly stronger financial outlook

Prostatype Genomics AB ("Prostatype Genomics" or "the Company") announces that its wholly-owned US subsidiary Prostatype Genomics Inc. has acquired a CLIA Certificate in its own name. Together with the announced CLIA laboratory agreement with Research Dx, this will enable the Company to enter the US prostate cancer market with its prognostic biomarker test Prostatype® upon accreditation from the CAP (College of American Pathologists) and formal technical validation of the Prostatype® test services. Prostatype Genomics expects to achieve these remaining steps and to initiate clinical use of

ResearchDx and Prostatype Genomics Inc. in CLIA-laboratory agreement for the US-market

Prostatype Genomics Inc. and ResearchDx, Irvine, California, USA, has entered into an agreement where ResearchDx fully integrated clinical laboratory PacificDx will perform and run the Prostatype®-test in the US-market.As previously communicated, Prostatype Genomics will offer its prognostic biomarker for diagnosed prostate cancer as a so called LDT-product in USA – similar to comparable products currently offered and reimbursed in USA. LDT stands for “Laboratory Developed Test” meaning that the product can be offered without an FDA-approval. What is required is a partnership with a CLIA-

Prostatype Genomics AB carries out a directed share issue to guarantors following completed rights issue

2024-01-16 09.40  NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION FURTHER REQUIRES PROSPECTUS, REGISTRATION, OR OTHER ACTIONS OTHER THAN THOSE UNDER SWEDISH LAW, ARE PROHIBITED, OR OTHERWISE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT TAKE PLACE WITHOUT APPLICATION OF EXCEPTIONS FROM SUCH ACTION. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF

Prostatype Genomics AB: Rights issue registered and trading in paid subscription units ceases

2024-01-16 09:30 Prostatype Genomics AB ("Prostatype Genomics" or the "Company") has completed a rights issue of units, consisting of shares and warrants of series 3, that closed on January 5, 2024. The rights issue is now registered with the Swedish Companies Registration Office and the last day of trading in paid subscription units (“BTU”) is January 17, 2024. The record date is January 19, 2024, after which BTUs are converted into shares and warrants of series 3 (“TO3”) on January 23, 2024. The new shares and TO3 warrants will be listed on Nasdaq First North Growth Market and the last

Prostatype Genomics announces final outcome of the Rights Issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION FURTHER REQUIRES PROSPECTUS, REGISTRATION, OR OTHER ACTIONS OTHER THAN THOSE UNDER SWEDISH LAW, ARE PROHIBITED, OR OTHERWISE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT TAKE PLACE WITHOUT APPLICATION OF EXCEPTIONS FROM SUCH ACTION. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.

Prostatype Genomics announces preliminary outcome of the Rights Issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION FURTHER REQUIRES PROSPECTUS, REGISTRATION, OR OTHER ACTIONS OTHER THAN THOSE UNDER SWEDISH LAW, ARE PROHIBITED, OR OTHERWISE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT TAKE PLACE WITHOUT APPLICATION OF EXCEPTIONS FROM SUCH ACTION. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.

Long term follow up study at Akademiska University Hospital, Uppsala, to be presented at EAU-meeting, May 2024: Indicates new area of use for Prostatype®

Prostatype Genomics has in collaboration with Akademiska University Hospital during 2023 initiated a comprehensive study in patients with localized prostate cancer over the course of 25 years. The study has been submitted to the prestigious and largest urology conference in Europe, the 39th Annual EAU (European Association of Urology) Congress. The congress received 5651 abstracts of various kinds, the highest number in many years. We can proudly announce that the new study from Akademiska University Hospital has been selected to present at the EAU Congress in Paris in May, 2024.

Prostatype Genomics publishes monthly newsletter and its net sales for the third quarter of 2023

Prostatype Genomics publishes a monthly newsletter with a company update by CEO Fredrik Persson and a long interview with CMO Gerald Andreoli about the clinical activities in the United States, including a large clinical validation study. At the same time, the company announces that its net sales for the third quarter of 2023 amounted to approx. 530 TSEK, compared to 109 TSEK for the same period last year.Prostatype Genomics will, starting in December 2023, publish monthly newsletters to provide more comprehensive information to shareholders, investors and other interested parties about the

Important information regarding the market capitalization value of Prostatype Genomics AB (publ) on certain financial websites

Prostatype Genomics AB (the "Company") regrettably informs that some financial websites providing information services on share data and other company information, such as Avanza, Nordnet and Dagens Industri, includes the Company's ongoing rights issue in their valuation as if it was already fully subscribed and also at the current share price. This gives of course an inaccurate picture of the Company's true value. The situation is reportedly a "standard procedure” but means that the Company's value before the outcome of the rights issue is closed, is misleading. This mechanics is

Prostatype Genomics AB: Prostatype Genomics publishes prospectus due to upcoming preferential share issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION FURTHER REQUIRES PROSPECTUS, REGISTRATION, OR OTHER ACTIONS OTHER THAN THOSE UNDER SWEDISH LAW, ARE PROHIBITED, OR OTHERWISE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT TAKE PLACE WITHOUT APPLICATION OF EXCEPTIONS FROM SUCH ACTION. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.

Communiqué from EXTRAordinary General Meeting in Prostatype Genomics AB (publ) held on 7 december 2023

Prostatype Genomics AB (publ), listed on the Nasdaq First North Growth Market, held an extraordinary general meeting today on 7 December 2023, whereby the following decisions were unanimously made. The extraordinary general meeting resolved to approve the board of directors’ resolution on 7 November 2023 to increase Prostatype Genomics share capital with a maximum of SEK 16,724,400.98 (the new quota value –SEK 0.01 – after the proposed reduction is applied) of which not more than SEK 11,946,000.70 refers to an increase due to an issue of shares, and not more than SEK 4,778,400.28 refers

Prostatype Genomics AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ)

Prostatype Genomics AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).Prostatype Genomics has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser to the company.

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe